Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b.
about
PEGylation of Interferon-β-1aThe anti-tumor agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), induces IFN-beta-mediated antiviral activity in vitro and in vivo.Severe immune thrombocytopenia after peg-interferon-alpha2a, ribavirin and telaprevir treatment completion: A case report and systematic review of literaturePeginterferon alfa-2a is associated with elevations in alanine aminotransferase at the end of treatment in chronic hepatitis C patients with sustained virologic responsePegylated interferon-α2a and ribavirin versus pegylated interferon-α2b and ribavirin in chronic hepatitis C : a meta-analysis.Biodegradable nanogels for oral delivery of interferon for norovirus infectionEfficacy and Tolerability of Peginterferon α -2a and Peginterferon α -2b, Both plus Ribavirin, for Chronic Hepatitis C: A Meta-Analysis of Randomized Controlled TrialsStudy of pruritus in chronic hepatitis C patients.Cost effectiveness and quality of life considerations in the treatment of hepatitis C infection.Prohibitin is overexpressed in Huh-7-HCV and Huh-7.5-HCV cells harboring in vitro transcribed full-length hepatitis C virus RNA.Uricases as therapeutic agents to treat refractory gout: Current states and future directions.Janus-like effects of type I interferon in autoimmune diseases.Anti-Viral Therapy and Decreased Sexual Desire in Patients with Chronic Hepatitis CGalactosylated Lipidoid Nanoparticles for Delivery of Small Interfering RNA to Inhibit Hepatitis C Viral Replication In Vivo.Treatment-emergent depression and anxiety between peginterferon alpha-2a versus alpha-2b plus ribavirin for chronic hepatitis C.PharmGKB summary: peginterferon-α pathway.Pegylated IFN-α regulates hepatic gene expression through transient Jak/STAT activation.Antiviral therapy: why does it fail in HCV-related chronic hepatitis?Peginterferon alfa-2a is superior to peginterferon alfa-2b in the treatment of naïve patients with hepatitis C virus infection: meta-analysis of randomized controlled trials.Controlled-release interferon alpha 2b, a new member of the interferon family for the treatment of chronic hepatitis C.The comparative efficacy and safety of peginterferon alpha-2a vs. 2b for the treatment of chronic HCV infection: a meta-analysis.Type I IFN-mediated regulation of IL-1 production in inflammatory disorders.Targeting the "cytokine storm" for therapeutic benefit.Standard and pegylated interferon therapy of HDV infection: A systematic review and meta- analysis.Detection of anti-cytokine antibodies and their clinical relevance.Effects of pharmaceutical PEGylation on drug metabolism and its clinical concerns.PEGylation and its impact on the design of new protein-based medicines.Drug-Drug Interactions Among Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Medications.Current views on interferon therapy for HIV.Type of pegylated interferon matters: another milestone in the treatment of hepatitis C virus infectionRole of the methoxy group in immune responses to mPEG-protein conjugates.Inhibition of hepatitis C virus replication by Monascus pigment derivatives that interfere with viral RNA polymerase activity and the mevalonate biosynthesis pathway.Intrapatient viral diversity and treatment outcome in patients with genotype 3a hepatitis C virus infection on sofosbuvir-containing regimens.Single centre experience with pegylated interferon and ribavirin for hepatitis C: looking back before moving forward.Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers.In Vivo SELEX of an Inhibitory NSCLC-Specific RNA Aptamer from PEGylated RNA Library.Peginterferon-Α_2B plus ribavirin is more effective than peginterferon-Α_2A plus ribavirin in menopausal women with chronic hepatitis C.[Alfa-interferons. Genetically engineered Antivirals].Elimination half-lives of interleukin-6 and cytokine-induced neutrophil chemoattractant-1 synthesized in response to inflammatory stimulation in rats.
P2860
Q22241420-7DE9BE63-9A33-42AB-8F7D-0F57A6324662Q30396361-264E3632-5BB2-4250-9F9F-526AD877EECDQ33424123-42A8BB88-6E99-4218-8191-6C81086040D1Q33769085-AFCB87F9-AC15-482F-BE76-20592B0B3424Q34329513-D6F86D3A-FFF6-4D98-B9CA-0A07E489EB17Q34525191-D4759C76-E432-4600-9E46-8F29C63424BEQ34714220-36AF76F8-36AF-41C1-9B8F-E95338E8286EQ34750602-2147B712-81D8-4993-820B-A47B8FE818BCQ35205389-DA136264-5682-478D-B769-7351BD8050E5Q35233150-624CC295-3A9E-40F6-93A3-48C9C295E262Q36002499-C83C5A77-CAB1-4BBF-B7BF-A30795670D28Q36059960-EE20F86A-F3FD-4E50-B300-E19BA15D4FA3Q36098942-E1C3E52B-3C9B-4CC8-A2F5-6319EA9B8FB4Q36172753-D90596C5-FEEA-4AB0-83CF-66753ADFFC1AQ36203547-DFC373EC-EFC5-405B-9D7D-A11605DD5528Q36590755-4F818375-B13B-40A4-A2A7-952367F1D810Q37679930-62302FB6-EBBD-49DF-B8E6-F823256BF00FQ37879193-75E866D4-FEBA-4AE7-A341-54E653AD2D0DQ37885222-BEDF4BA8-58FF-4DE4-9F9A-B7C5CD63742BQ37962692-8A94CA9B-092F-4580-8B8D-A2ECEB27529CQ37982063-DAACD384-4D8E-4A64-A36B-FEB63CFAA17EQ38004932-9A5FDAD3-33AB-48DB-B902-FF0C05B4DEFAQ38071254-2EB39BAD-29A6-4B7D-BA43-1D70269762EEQ38119225-41C6E87E-8F79-4B45-8AA0-AB856757B393Q38217701-70810428-DA27-4F99-AF72-D34360302FABQ38255726-077CFD0E-A74E-43EB-A435-3553420496AFQ38269324-86B23085-0EDD-426A-A1F6-D30F71CCEC63Q38432073-D2316BBD-72ED-479E-9101-2999945013CBQ38860634-E66D2C7F-12B4-4EE4-9AB6-0EC17CCA4315Q40753560-6215294C-92D0-4F0B-A5F8-4BB6E83583E8Q41940240-EB8FDC70-EA76-47FD-B186-80F9A745D27EQ43042322-4A6C6C37-0133-4137-BB84-132C78C07666Q45325188-CD9A4DA7-1EF1-4E43-B468-C7CCF4FF45EFQ45836877-A2E471A2-3BCC-4C7F-B43D-03FE48D721E7Q47231847-A486F65E-751A-45EB-A13B-B7C40204F841Q49196378-D08449AA-8666-43F1-8142-F382BB5C5308Q50551487-6B35238B-D1BA-4FA1-A54A-C5081A56A985Q54160839-BA0B96AC-1380-4236-B7F0-DC6151A2FF1BQ55290857-D59E942E-347D-4ED8-BDCA-AA01D689A2B7
P2860
Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Pegylated interferons for the ...... 2a and peginterferon-alpha-2b.
@ast
Pegylated interferons for the ...... 2a and peginterferon-alpha-2b.
@en
Pegylated interferons for the ...... 2a and peginterferon-alpha-2b.
@nl
type
label
Pegylated interferons for the ...... 2a and peginterferon-alpha-2b.
@ast
Pegylated interferons for the ...... 2a and peginterferon-alpha-2b.
@en
Pegylated interferons for the ...... 2a and peginterferon-alpha-2b.
@nl
prefLabel
Pegylated interferons for the ...... 2a and peginterferon-alpha-2b.
@ast
Pegylated interferons for the ...... 2a and peginterferon-alpha-2b.
@en
Pegylated interferons for the ...... 2a and peginterferon-alpha-2b.
@nl
P2860
P1433
P1476
Pegylated interferons for the ...... 2a and peginterferon-alpha-2b.
@en
P2093
Graham R Foster
P2860
P304
P356
10.2165/11531990-000000000-00000
P577
2010-01-01T00:00:00Z
P6179
1044222206